RxDoctor Payments Data

Brian Nolan, MD

Vascular Surgery · Lebanon, NHNPI 1144337569

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (36.9%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. Boston Scientific accounts for 66.0% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2019 at $7,447 and has fallen 98.1% since, to $140 in 2024.

$8,133in general payments, 2019–2025

Across 33 payments — averaging $246.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$5K
  • Silk Road Medical, Inc.$2K
  • W. L. Gore & Associates, Inc.$270
  • Medtronic$166
  • Endologix LLC$121
$2,364in research payments, 2019–2025

Across 1 payment — averaging $2364.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$2K

What the payments were for

  • Consulting fees$3,00037%
  • Travel & lodging$3,00037%
  • Food & beverage$2,13326%

General payments by program year

19
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,133 in reported general payments places this provider in the 80th percentile of 43 vascular surgery providers in New Hampshire.

See all vascular surgery providers in New Hampshire

Medicare billing

Part B allowed, 2024
$39,247
Medicare patients
101
Services billed
196

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cilostazol12$257

Paid to pharmacies, not to this prescriber.

Other vascular surgery in Lebanon

See the full list for New Hampshire

Where these figures come from

Is this you, or does something look wrong? →